Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Pirfenidone (200mg)
Therapeutic Category
Pulmonary, Respiratory
Dosage Form
Tablet
Packaging Type
Blister
Packaging
2x15
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Pifetol 200 Tablet is a pharmaceutical product containing Pirfenidone, a medication primarily used in the treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic lung disease characterized by progressive scarring of the lung tissue. Pirfenidone is an anti-fibrotic agent that helps slow down the progression of lung fibrosis by reducing inflammation and the formation of scar tissue in the lungs, improving lung function and slowing the decline in lung capacity.
Pirfenidone works by modulating the growth factors and cytokines involved in fibrosis and inflammation, leading to a reduction in the activity of the fibrotic process. It is believed to act by inhibiting the production of transforming growth factor-beta (TGF-β), a key driver of fibrotic activity, and reducing the synthesis of collagen. This helps improve the quality of life for patients suffering from IPF and may prolong survival by reducing the rate of lung function decline.
In addition to its effectiveness in IPF, Pirfenidone is being researched for other fibrotic conditions, but it is currently approved for use in the management of IPF. Patients taking Pifetol 200 Tablet may experience benefits in lung function, but consistent monitoring and regular follow-ups with healthcare providers are essential.
Common side effects include nausea, fatigue, anorexia, diarrhea, and liver enzyme abnormalities. Rare but serious side effects may include liver toxicity and skin reactions.
For the treatment of Idiopathic Pulmonary Fibrosis (IPF) to slow disease progression and improve lung function.
Regular liver function tests should be performed during treatment. Discontinue use if severe liver damage occurs.
Store in a cool, dry place, away from direct light. Keep out of reach of children.
Composition : Montelukast (10mg) + Fexofenadine (120mg)
Composition : Montelukast (10mg) + Fexofenadine (120mg) + Acebrophylline (200mg) (Sustained Release)
Composition : Bilastine (20mg) Tablet
Composition : Bilastine (10mg) tablet
Composition : Cetirizine (10mg) Tablet
Composition : Chlorpheniramine Maleate (2mg) + Paracetamol (500mg) + Phenylephrine (10mg)
Composition : Levocetirizine (5mg) + Montelukast (10mg) Bilayered
Composition : Levocetirizine (2.5mg) + Montelukast (4mg) Bilayered
Composition : Desloratadine (5mg) + Montelukast (10mg)
Composition : Loratadine (10mg) Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Pirfenidone 200 mg Tablet is an antifibrotic and lung-protective pharmaceutical formulation used for the management of idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic lung conditions. It works by reducing fibroblast proliferation, inflammation, and collagen formation in lung tissue, thereby slowing disease progression and improving lung function stability. It is a valuable pulmonology and specialty chronic care segment product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent and long-term demand from pulmonologists, chest physicians, and multispecialty hospitals. As IPF is a chronic and progressive condition requiring continuous therapy, it ensures regular prescriptions, long-duration treatment cycles, and stable institutional demand.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the pulmonology, critical care, and chronic specialty segments with monopoly rights, quality manufacturing standards, regulatory compliance, and reliable supply support for distributors and medical agencies.
Wholesalers and healthcare suppliers benefit from specialist-driven demand, long-term chronic therapy usage, hospital and pulmonology clinic prescriptions, and steady institutional procurement, making it a stable and high-value pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in pulmonology and antifibrotic specialty formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the respiratory and chronic care segment.